GlassScriptPhysician profile
Nicholas Taylor
NPI 1952706624
$6,045.70
in general payments reported to CMS, 2019-2025
30 companies · $889 in 2025
The $889 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $576 · 2022: $1,175 · 2023: $1,734 · 2024: $1,672 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $805.91 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $685.08 | 2021-2025 | Camzyos, Eliquis |
| Abbvie INC. | $645.55 | 2021-2025 | |
| Pfizer INC. | $399.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $373.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $369.90 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $341.99 | 2022-2024 | |
| Shionogi INC | $274.36 | 2023-2024 | Fetroja |
| Abbott Laboratories | $267.74 | 2023-2024 | Mitraclip, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.03 | 2023-2024 | Jardiance |
| Viatris Specialty LLC | $201.88 | 2025 | Yupelri |
| Endo Pharmaceuticals INC. | $175.16 | 2021-2023 | Xiaflex, Aveed |
| United Therapeutics Corporation | $148.72 | 2023-2025 | Remodulin, Orenitram |
| Alexion Pharmaceuticals, INC. | $147.52 | 2023 | Soliris, Ultomiris |
| Novo Nordisk INC | $123.03 | 2025 | Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $116.55 | 2024 | Inpefa |
| Mylan Specialty L.P. | $109.27 | 2024 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.72 | 2024-2025 | Lifevest |
| Lilly USA, LLC | $91.04 | 2024 | |
| Merck Sharp & Dohme LLC | $90.32 | 2021-2025 | Verquvo, Recarbrio, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $76.05 | 2024-2025 | Terlivaz |
| Vertex Pharmaceuticals Incorporated | $49.99 | 2025 | |
| Janssen Biotech, INC. | $49.77 | 2022-2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $49.42 | 2022-2024 | Andexxa |
| Cvrx, INC. | $31.73 | 2025 | Barostim Neo System |
| Inari Medical, INC. | $29.71 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gilead Sciences, INC. | $24.62 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.69 | 2022 | |
| Global Blood Therapeutics, INC. | $19.97 | 2021 | |
| Smith+Nephew, INC. | $17.46 | 2023 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.